Abcam, ab169052, Anti-TRA2A antibody

Size: 50µg
Mouse Polyclonal TRA2A antibody. Suitable for WB, ICC/IF and reacts with Mouse, Human samples. Cited in 2 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human TRA2A.
Key facts
Host species:Mouse,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Human,
Applications:ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Full Length Protein corresponding to Human TRA2A.Q13595

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TRA2A also known as transformer 2 alpha homolog is an RNA-binding protein involved in numerous cellular processes. This protein has a molecular weight of approximately 31 kDa. It is expressed in many tissues including the brain and testes. TRA2A binds to specific RNA sequences modulating splicing events and affecting the choice of splice sites. It belongs to the serine/arginine-rich protein family which plays key roles in the regulation of both alternative and constitutive splicing.
Biological function summary
TRA2A influences gene expression and transcript variants by engaging in complex interactions. It acts as part of the spliceosome machinery which is a large ribonucleoprotein complex responsible for splicing pre-mRNA. TRA2A ensures precise removal of introns and ligation of exons producing different mRNA isoforms. These isoforms translate into functionally distinct proteins influencing cellular activity.
Pathways
TRA2A participates in the mRNA processing pathway influencing genetic output by regulating splice site selection. TRA2A connects to the MAPK signaling pathway as it is known to interact with proteins like SAM68 which also affects mRNA splicing. This connectivity with other proteins highlights the regulatory network's complexity ensuring accurate gene expression profiles.
TRA2A has been implicated in cancer and neurodegenerative disorders. Altered expression and splicing activity of TRA2A contribute to oncogenesis as seen in breast cancer where abnormal splicing can drive tumor progression. TRA2A also impacts neurological conditions interplaying with proteins like tau in Alzheimer's disease where aberrant splicing plays a part in disease pathology. Understanding these links offers potential therapeutic angles for targeting TRA2A-related pathways.